DEINOVE announces a new R&D project in animal nutrition with Flint Hills Resources

03.11.2015
  • The program targets the production of ingredients for animal feed using Deinococcus bacteria and raw material provided by Flint Hills Resources, a U.S. company active in biofuels, specialty ingredients, refining and chemicals

DEINOVE (Alternext Paris: ALDEI), a biotech company developing innovative processes for producing biofuels and bio-based chemicals by using Deinococcus bacteria as host strains, today announces an agreement with Flint Hills Resources to develop a process for producing ingredients for animal nutrition.

Flint Hills Resources, a subsidiary of KOCH INDUSTRIES - one of the largest private companies in the world - is a leading refining, petrochemical and biofuels company in the United States.

Both companies aim to develop conditions for an industrial biological production process based on selected bacteria from DEINOVE and raw materials supplied by Flint Hills Resources. Over the next 17 months DEINOVE will screen its library of 6,000 strains, identify and optimize bacteria that are able to grow in good conditions using raw materials supplied by Flint Hills Resources and produce the targeted compounds in acceptable quantities. 

Flint Hills Resources is covering the costs of the R&D project. The company is not disclosing the cost of the investment.  

If successful, the two companies will study the terms of a licensing agreement for the technology developed by the R&D project.

 “We are excited to work with Deinove on this project and drive innovation that we believe has the potential to add value to an increasingly important market segment and enhance the  overall profile of our U.S. biofuels business,” said Dr. Jeffrey Miano, Director of New Ventures at Flint Hills Resources.

"This collaboration with Flint Hills Resources allows us to expand our potential in the animal feed market where we are already active within other projects," added Emmanuel Petiot, CEO of DEINOVE. "The extremely diverse potential of Deinove's bank of strains offers many opportunities for value creation. This new project is just one example of it."